| Treatment of Moderate to Severe Lateral Canthal Lines (NCT04249687) | Galderma R&D | 2020-02-10 |
| Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines (NCT04225260) | Galderma R&D | 2020-01-27 |
| MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) (NCT04157686) | Medy-Tox | 2019-10-23 |
| Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines (NCT04143854) | Medy-Tox | 2019-05-21 |
| Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines (NCT03911102) | Revance Therapeutics, Inc. | 2019-03-11 |
| MT10109L in the Treatment of Lateral Canthal Lines (NCT03785145) | Medy-Tox | 2018-12-20 |
| MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines (NCT03732833) | Medy-Tox | 2018-11-05 |
| MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) (NCT03721016) | Medy-Tox | 2018-10-26 |
| Princess® RICH for the Correction of Fine Lines (NCT03923634) | Croma-Pharma GmbH | 2018-10-16 |
| ET-01 in Subjects With Lateral Canthal Lines, LCL-208 (NCT03839693) | Eirion Therapeutics Inc. | 2018-10-16 |
| ET-01 in Subjects With Lateral Canthal Lines (NCT03326856) | Eirion Therapeutics Inc. | 2017-10-25 |
| Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea (NCT02248844) | Allergan | 2014-09-26 |
| BOTOX® in the Treatment of Crow's Feet Lines in China (NCT02195687) | Allergan | 2014-09-01 |
| Dose Finding Study In Subjects With Crow's Feet (NCT01951742) | Anterios Inc. | 2013-09-01 |
| Clinical Trial to Evaluate ANT-1401 in Crow's Feet (NCT01809964) | Anterios Inc. | 2013-03-01 |
| Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet (NCT01358695) | Anterios Inc. | 2011-05-01 |
| Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults (NCT01124565) | Revance Therapeutics, Inc. | 2010-05-01 |
| Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults (NCT01064518) | Revance Therapeutics, Inc. | 2010-01-01 |
| Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines (NCT00968942) | Revance Therapeutics, Inc. | 2009-08-01 |
| Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines (NCT00968825) | Revance Therapeutics, Inc. | 2009-07-01 |
| Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines (NCT00907387) | Revance Therapeutics, Inc. | 2009-04-01 |
| Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines (NCT00884234) | Revance Therapeutics, Inc. | 2009-02-01 |
| Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines (NCT00888914) | Revance Therapeutics, Inc. | 2008-11-01 |
| Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet) (NCT00247559) | Ipsen | 2004-05-01 |